The European Commission has mounted a robust defence of its decision not to approve an orphan drug from a French company against the advice of the European Medicines Agency's scientific committee, the CHMP, and the standing committee of member state representatives1.
European Commission defends non-approval of orphan drug amid claims of "favouritism"
The European Commission has mounted a robust defence of its decision not to approve an orphan drug from a French company against the advice of the European Medicines Agency's scientific committee, the CHMP, and the standing committee of member state representatives1.
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.